Submit Deal

Announced

6 Sep 2022

Equillium failed to acquire Metacrine for $33m.

Synopsis

Equillium, a biotechnology company, failed to acquire Metacrine, a clinical-stage bio pharmaceutical company, for $33m. On December 23, 2022, Metacrine and Equillium announced the mutual termination of their previously announced definitive merger agreement. Metacrine is continuing to evaluate all strategic opportunities.

Principals

target

Metacrine

bidder

EQUILLIUM

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (1)

preston klassen

CEO at METACRINE INC

Manager

target

Deal

£ 29 M

Total Value

Bidder Team (11)

thomas a. coll

Partner at Cooley

Lawyer

bidder

Deals

£ 1.29 B

Total Value

christophe y. beauduin

Special Counsel at Cooley

Lawyer

bidder

Deals

£ 4.42 B

Total Value

brenden rowook park

Associate at Cooley

Lawyer

bidder

Deals

£ 66.83 B

Total Value

dylan kornbluth

Associate at Cooley

Lawyer

bidder

Deals

£ 1.89 B

Total Value

daniel p. herrmann

Associate at Cooley

Lawyer

bidder

Deals

£ 104.39 B

Total Value

rama padmanabhan

Partner at Cooley

Lawyer

bidder

Deals

£ 44.16 B

Total Value

amanda pacheco

Associate at Cooley

Lawyer

bidder

Deals

£ 29.24 B

Total Value

rajdeep roger bains

Associate at Cooley

Lawyer

bidder

Deals

£ 16.36 B

Total Value

jeffrey tolin

Partner at Cooley

Lawyer

bidder

Deals

£ 85.47 B

Total Value

charity williams

Associate at Cooley

Lawyer

bidder

Deals

£ 15.00 B

Total Value

michael moore

Vice President, Investor Relations & Corporate Communications at EQUILLIUM

Manager

bidder

Deals

£ 297 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy